Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short term Debt: 2009-2025

Historic Short term Debt for Aytu Biopharma (AYTU) over the last 14 years, with Sep 2025 value amounting to $14.9 million.

  • Aytu Biopharma's Short term Debt rose 248.31% to $14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.9 million, marking a year-over-year increase of 248.31%. This contributed to the annual value of $9.1 million for FY2025, which is 278.41% up from last year.
  • As of Q3 2025, Aytu Biopharma's Short term Debt stood at $14.9 million, which was up 64.11% from $9.1 million recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Short term Debt peaked at $16.7 million during Q2 2021, and registered a low of $1.0 million during Q4 2023.
  • Over the past 3 years, Aytu Biopharma's median Short term Debt value was $4.3 million (recorded in 2024), while the average stood at $6.7 million.
  • In the last 5 years, Aytu Biopharma's Short term Debt spiked by 1,597.35% in 2021 and then slumped by 86.19% in 2023.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Short term Debt stood at $16.3 million in 2021, then slumped by 54.54% to $7.4 million in 2022, then crashed by 86.19% to $1.0 million in 2023, then skyrocketed by 291.03% to $4.0 million in 2024, then spiked by 248.31% to $14.9 million in 2025.
  • Its Short term Debt stands at $14.9 million for Q3 2025, versus $9.1 million for Q2 2025 and $10.0 million for Q1 2025.